Combination ICI and patient selection criteria for ICIs were explored in the Phase 2 NIMBUS trial, which enrolled patients with HER2-negative advanced breast cancer (TNBC and hormone-receptor positive [HR+]) and TMB-high rather than utilizing PD-L1 expression [31]. The gene discussed is CD274; the disease is breast cancer.